NIKKEI 225
40,580.76 +506.06 (+1.26%) HANG SENG
17,978.57 +209.47 (+1.18%) CRUDE OIL
83.88 0.00 (0.00%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
47,284.34 -1,369.67 (-2.82%)
ZNTL Oct 2024 12.500 call
- GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on July 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 40,875 shares of the Company’s common stock to five newly hired empl
- Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
- Zacks
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
